Highest-materiality recent filing
Hepion Pharmaceuticals raises $700,000 in private placement of 17.5 million shares
Hepion entered securities purchase agreements with accredited investors on April 21, 2026, selling 17,500,000 shares at $0.04 per share.
Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment
Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.
Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO
CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.
Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics
Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.
Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K
Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.
Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named
John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.
Hepion shareholders reject reverse stock split amendment at 2025 annual meeting
Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.
Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16
Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.
Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones
Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.
On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.
Max materiality 0.80 · Median 0.60 · Most common event leadership